A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease

An Open Label Study of the Efficacy, Safety, and Pharmacoeconomics of Oral Ibandronate (Bondronat 50 mg) in Treatment of Metastatic Bone Disease

This study will evaluate the efficacy, safety, and effect on quality of life of oral ibandronate (Bondronat) in participants with breast cancer and metastatic bone disease. The anticipated time on study treatment is 25 weeks, and the target sample size is 50 individuals.

Inclusion Criteria:

• Females at least 18 years of age
• Breast cancer
• Bone metastases

Exclusion Criteria:

• Use of bisphosphonates within the last 3 months
• Prior use of gallium nitrate or metastron
• Severely impaired renal function
• Hypocalcemia or primary hyperparathyroidism
• Central nervous system (CNS) metastases